Stockscreener 앱 받기
29.12
3.03%
-0.91
전일 마감가:
$30.03
열려 있는:
$28.9
하루 거래량:
706.62K
Relative Volume:
0.66
시가총액:
$1.27B
수익:
-
순이익/손실:
$-38.35M
주가수익비율:
-20.08
EPS:
-1.45
순현금흐름:
$-36.91M
1주 성능:
+15.28%
1개월 성능:
+24.98%
6개월 성능:
+766.67%
1년 성능:
+535.81%
1일 변동 폭
$28.11
$32.56
1주일 범위
$19.85
$32.56
52주 변동 폭
$2.01
$38.33
Galecto Inc Stock (GLTO) Company Profile
명칭
Galecto Inc
전화
45-70-70-52-10
주소
75 STATE STREET, BOSTON
Compare GLTO vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GLTO
Galecto Inc
|
29.12 | 1.31B | 0 | -38.35M | -36.91M | -1.45 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Galecto Inc Stock (GLTO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-07 | 개시 | Leerink Partners | Outperform |
| 2025-12-01 | 개시 | Guggenheim | Buy |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-11-23 | 개시 | BofA Securities | Buy |
| 2020-11-23 | 개시 | Credit Suisse | Outperform |
| 2020-11-23 | 개시 | SVB Leerink | Outperform |
모두보기
Galecto Inc 주식(GLTO)의 최신 뉴스
What is Galecto Inc.’s valuation compared to sector2025 Winners & Losers & Weekly Stock Performance Updates - mfd.ru
Why Galecto Inc. stock could be next big winnerDip Buying & AI Enhanced Market Trend Forecasts - mfd.ru
Galecto Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.3 Million - Bitget
Galecto raises $316.3M as it develops blood cancer therapies - Stock Titan
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Dividend Watch: Can Galecto Inc lead its sector in growthEarnings Miss & High Conviction Buy Zone Picks - baoquankhu1.vn
Galecto prices $275 million public offering at $19 per share By Investing.com - Investing.com Nigeria
Galecto Prices Upsized Public Offering to Fund DMR-001 - TipRanks
Galecto Signs Underwriting Agreement With Jefferies and Leerink Partners - TradingView
Galecto shares fall after $275 million equity raise at discount By Investing.com - Investing.com South Africa
GLTO: Key Managers Involved in Recent Offering - GuruFocus
Galecto to raise USD 275m in share issue - medwatch.com
Galecto Prices $275 Mln Public Offering At $19 Per Share, Stock Down - Nasdaq
Cancer drug developer Galecto raises $275M in stock sale - Stock Titan
Hans Schambye resigns from Galecto – takes top position at Boost Pharma - medwatch.com
Galecto Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock - 富途牛牛
Galecto Prices $275 Million Offering - marketscreener.com
Galecto Announces Pricing of $275 Million Underwritten Public Offering - The Manila Times
Galecto, Inc. Announces Pricing of $275 Million Underwritten Public Offering of Common Stock - Quiver Quantitative
Galecto announces pricing of $275 million underwritten public offering - marketscreener.com
Galecto Announces Pricing of $275 Million Underwritten Public Offering - GlobeNewswire Inc.
Galecto announces public offering of common stock and preferred shares By Investing.com - Investing.com Nigeria
Hans Schambye on Galecto exit: It happened by mutual agreement - medwatch.com
Galecto stock falls after announcing public offering of common stock - Investing.com India
Galecto stock falls after announcing public offering of common stock By Investing.com - Investing.com South Africa
Galecto (GLTO) Files Automatic Mixed Securities Shelf - GuruFocus
Galecto announces public offering of common stock and preferred shares - Investing.com
Cancer drug developer Galecto plans stock sale to fund antibody trials - Stock Titan
Galecto announces CEO transition, share authorization increase, and shareholder approvals - Investing.com Canada
Galecto announces CEO transition, share authorization increase, and shareholder approvals By Investing.com - Investing.com South Africa
Galecto CEO Transition and Major Shareholder-Approved Restructuring - TipRanks
Galecto (NASDAQ: GLTO) CEO departs amid big share increase and Cayman move - Stock Titan
Returns Recap: How sensitive is Galecto Inc to inflation2025 Market Outlook & High Yield Equity Trading Tips - baoquankhu1.vn
Galecto (NASDAQ:GLTO) Raised to Strong-Buy at Lifesci Capital - Defense World
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Galecto (GLTO), Roche Holding AG (OtherRHHVF) and Amgen (AMGN) - The Globe and Mail
Growth Report: Will Galecto Inc announce a stock splitJuly 2025 Sector Moves & Stepwise Trade Signal Implementation - baoquankhu1.vn
How sensitive is Galecto Inc to inflationTrade Performance Summary & Daily Momentum Trading Reports - baoquankhu1.vn
Galecto Showcases New mutCALR MPN Pipeline at JPM - TipRanks
Risk Report: Is dMY Squared Technology Group Inc Equity Warrant likely to announce a buybackJuly 2025 Update & Entry Point Confirmation Signals - baoquankhu1.vn
Is Galecto Inc a stock for growth or value investorsJuly 2025 EndofMonth & Verified Swing Trading Watchlist - baoquankhu1.vn
Fund Flows: Should I set a stop loss on CNFR2025 Price Targets & Community Consensus Trade Signals - baoquankhu1.vn
Exit Recap: What is Dow Incs book value per sharePortfolio Value Summary & Technical Buy Zone Confirmations - baoquankhu1.vn
Is Galecto Inc. stock supported by innovation pipelineTechnical Breakout Signals & Maximize Gains Professionally - Bollywood Helpline
Galecto, Inc. (NASDAQ:GLTO) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Movement Recap: Is Galecto Incs ROIC above industry averageJuly 2025 Setups & Community Verified Watchlist Alerts - baoquankhu1.vn
Galecto (GLTO) Price Target Increased by 13.89% to 41.82 - Nasdaq
Investment Recap: Can Galecto Inc stock double in next 5 yearsEarnings Recap Report & Safe Entry Point Alerts - Bộ Nội Vụ
Galecto on track to submit IND for mutCALR antibody by mid-2026 - Investing.com Nigeria
Galecto on track to submit IND for mutCALR antibody by mid-2026 By Investing.com - Investing.com India
Galecto Inc (GLTO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.12%
0.87%
자본화:
|
볼륨(24시간):